Identifying biomarkers and imaging markers for intracerebral hemorrhage
Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients
This study is trying to find new blood and imaging tests that can help doctors better understand and treat patients who have had a severe type of stroke called intracerebral hemorrhage.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Southwest Hospital, China Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06462274 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on intracerebral hemorrhage (ICH), a severe type of stroke that leads to high mortality and disability. Researchers aim to discover potential biomarkers by analyzing blood, cerebrospinal fluid, urine, saliva, and tissue samples from ICH patients, alongside conducting multimodal imaging scans such as CT, MRI, MRS, and PET. The goal is to enhance understanding of the pathophysiological mechanisms of ICH and develop new tools for diagnosis, monitoring, and prognosis. By correlating molecular and imaging markers, the study seeks to improve therapeutic decisions and risk stratification for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-80 years with a spontaneous intracerebral hemorrhage confirmed by CT scan and a hematoma size greater than 5 ml.
Not a fit: Patients with ICH due to aneurysms, arteriovenous malformations, tumors, or trauma, as well as those with severe organ dysfunction, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients suffering from intracerebral hemorrhage.
How similar studies have performed: While the approach of identifying biomarkers and imaging markers is promising, it remains largely novel and untested in the specific context of intracerebral hemorrhage.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals aged 18-80 years 2. Hematoma size is more than 5 ml 3. Evidence of a spontaneous ICH on CT scan 4. Patient within 72 hours of ictus 5. Glasgow Coma Scale (GCS) Score of 5-15. 6. The history of hypertension Exclusion Criteria: 1. Individuals with age \< 18 years or \> 80 years 2. Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases. 3. ICH secondary to tumor or trauma.. 4. If the haematological effects of any previous anticoagulants are not completely reversed. 5. Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.
Where this trial is running
Chongqing, Chongqing Municipality
- Department of Neurosurgery , Southwest Hospital, Third Military Medical University, — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Rong Hu, Ph.D — Southwest Hospital, China
- Study coordinator: Rong Hu, Ph.D
- Email: huchrong@aliyun.com
- Phone: 86-23-68765761
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.